PCSK9抑制剂的使用正在为临床上难治性高胆固醇血症以及他汀类药物不耐受的患者群体开辟全新的治疗前景。 1月10日，恒瑞医药的一款抗PCSK9药物瑞 ...

近年来，一种新型降脂药物——PCSK9抑制剂进入临床应用，药物通过皮下注射的方式给药，具有长效性和便捷性的优势，可以每2周到每6个月注射一次 ...

对此，近年来备受瞩目的PCSK9单抗类药物与他汀类药物的联合治疗方案应用越来越广泛，但在给药频率上仍存在一定局限性，患者需要每日服用他汀 ...

There are two antibodies already on the market that target PCSK9 – Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Repatha (alirocumab) – but these require subcutaneous injection every ...

对此，近年来备受瞩目的PCSK9单抗类药物与他汀类药物的联合治疗方案应用越来越广泛，但在给药频率上仍存在一定局限性，患者需要每日服用他汀 ...

对此，近年来备受瞩目的PCSK9单抗类药物与他汀类药物的联合治疗方案应用越来越广泛，但在给药频率上仍存在一定局限性，患者需要每日服用他汀 ...

Injectable antibodies targeting PCSK9 have failed to take off as expected ... given as once- or twice-monthly monthly injections – were hailed as blockbusters-in-waiting when they launched ...

Although PCSK9 is a promising genetic target ... from daily pills and intermittent injections to advanced gene-editing therapies. Although not every patient will be comfortable with a gene ...

Researchers have found in Phase 3 LIBerate-HoFH trial that Lerodalcibep, a third-generation PCSK9 inhibitor, showed similar ...